A single-center prospective analysis of the impact of glucose metabolism on pancreatic fistula onset after pancreaticoduodenectomy for periampullary tumors
Giuseppe Quero,Vito Laterza,Gianfranco Di Giuseppe,Chiara Lucinato,Giuseppe Massimiani,Enrico Celestino Nista,Francesco Sionne,Beatrice Biffoni,Michela Brunetti,Fausto Rosa,Davide De Sio,Gea Ciccarelli,Claudio Fiorillo,Roberta Menghi,Lodovica Langellotti,Laura Soldovieri,Antonio Gasbarrini,Alfredo Pontecorvi,Andrea Giaccari,Sergio Alfieri,Vincenzo Tondolo,Teresa Mezza
DOI: https://doi.org/10.1016/j.amjsurg.2024.115987
2024-09-24
Abstract:Background: Glucose impairment notably affects the postoperative course of gastrointestinal surgeries. However, evidence on its impact on clinically relevant pancreatic fistulas(CR-POPFs) after pancreaticoduodenectomy(PD) is lacking. This study evaluates if and how preoperative glucose metabolism affects the development of CR-POPF after PD. Methods: One hundred and ten consecutive PDs were included. Patients underwent preoperative metabolic profiling using the Oral Glucose Tolerance Test(OGTT) and the hyperinsulinemic euglycemic clamp procedure. Accordingly, patients were categorized as normal glucose tolerant (NGT), impaired glucose tolerant (IGT), diabetic (DM), and longstanding-DM. Receiver operating characteristics(ROC) analyses were performed to determine the values of metabolic features in prediction of CR-POPF. Results: The CR-POPF rate was 36.3 %(40 patients). NGT patients had a higher CR-POPF rate (51.7 %) compared to IGT(45.2 %), DM (15.8 %), and longstanding-DM (25.8 %) (p = 0.03). CR-POPF patients had lower median fasting glucose levels (p = 0.01) and higher c-peptide values at all OGTT time points (p < 0.05). Fasting glucose and c-peptide levels had high diagnostic accuracy for CR-POPF (AUC>0.8) and were independent risk factors for CR-POPF (OR: 24.7[95%CI: 3.7-165.3] for fasting glucose; OR: 19.9[95%CI: 3.2-125.3] for c-peptide). Conclusion: Normoglycemia and normal beta cell function may be risk factors for CR-POPF after PD. Fasting glucose and c-peptide levels effectively predicted CR-POPF development following PD. Clinicaltrials gov identifier: NCT02175459.